# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC Filing
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $50 price target.
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy, adjusts target to $30 ...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday. The Dow traded do...
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected four...